Effect of intraoral and subcutaneous morphine on dyspnea at rest in terminal patients with primary lung cancer or lung metastases

Journal of Opioid Management

Volumn 9, Issue 4, 2013, Pages 269-274

  Gamborg, Helle ^a   Riis, Jette ^a   Christrup, Lona ^b   Krantz, Torben ^a  

^a Sankt Lukas Stiftelsens Hospice   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Lung neoplasms; Opioid substitution therapy; Pulmonary ventilation

Indexed keywords

MORPHINE; PREDNISOLONE;

ADULT; AGED; ARTICLE; BREATHING RATE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DYSPNEA; FEMALE; HUMAN; LUNG CANCER; LUNG METASTASIS; MALE; ORAL DROPS; OXYGEN SATURATION; PRIMARY TUMOR; PULSE OXIMETRY; PULSE RATE; TERMINALLY ILL PATIENT; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; DENMARK; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HEART RATE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORPHINE; RESPIRATORY RATE; TERMINAL CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84886708070     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2013.0168     Document Type: Article

References (16)

1. Ripamonti C, Bruera E: Dyspnea: Pathophysiology and assessment. J Pain Symptom Manage. 1997; 13: 220-232. (Pubitemid 27200985)
2. Reuben DB, Mor V: Dyspnea in terminally ill cancer patients. Chest. 1986; 89: 234-236. (Pubitemid 16156422)
3. Williams CM: Dyspnea. Cancer J. 2006; 12: 365-373.
4. Mazzocato C, Buclin T, Rapin CH: The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double-blind controlled trail. Ann Oncol. 1999; 10: 1511-1514. (Pubitemid 30017064)
5. Allard P, Lamontagne C, Bernard P, et al.: How effective are supplementary dose of opioids for dyspnea in terminal ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage. 1999; 17(4): 256-265. (Pubitemid 29159968)
6. Clemens KE, Quednau I, Klaschik E: Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliative Med. 2008; 11(2): 204-216. (Pubitemid 351374202)
7. Ben-Aharon I, Gafter-Gvilli A, Leibovici L, et al.: Interventions for alleviating cancer-related dyspnea: A systematic review and meta-analysis. Acta Oncol. 2012; 51: 996-1008.
8. Jennings AL, Davies AN, Higgins JP, et al.: Opioids for the palliation of breathlessness in terminal illness (Review). The Cochrane Collaboration. 2008; 4: 1-35.
9. Bruera E, Macmillan K, Pither J, et al.: Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage. 1990; 5(6): 341-344.
10. Bruera E, MacEachern T, Ripamonti C, et al.: Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med. 1993; 119(9): 906-907. (Pubitemid 23316875)
11. Watson NW, Taylor KM, Joel SP, et al.: A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers. J Pharmacy Pharmacol. 1996; 48(12): 1256-1259. (Pubitemid 27035914)
12. Osborne R, Joel SP, Trew D, et al.: Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990; 47: 12-19. (Pubitemid 20041204)
13. Hoskin PJ, Hanks GW, Aherne GW, et al.: The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol. 1989; 27(4): 499-505. (Pubitemid 19101158)
14. Davis T, Miser AW, Loprinzi C, et al.: Comparative morphine pharmacokinetics following sublingual, intramuscular and oral administration in patients with cancer. Hospice J. 1993; 9: 85-90.
15. Säwe J, Dahlström B, Paalzow L, et al.: Morphine kinetics in cancer patients. Clin Pharmacol Ther. 1981; 30: 629-635.
16. Bausewein C, Farquhar M, Booth S, et al.: Measurement of breathlessness in advanced disease: A systematic review. Respir Med. 2007; 101: 399-410. (Pubitemid 46205909)